前列地尔联合倍他司汀治疗椎-基底动脉供血不足的疗效分析

目的观察前列地尔联合倍他司汀治疗椎-基底动脉供血不足的临床疗效。方法将136例椎-基底动脉供血不足患者随机分为前列地尔联合倍他司汀治疗组(68例)和倍他司汀对照组(68例),观察临床疗效及治疗前后椎-基底动脉平均血流速度的改善情况。结果治疗组治愈率及总有效率高于对照组(P<0.05);治疗组各动脉平均血流速度均明显较对照组改善(P<0.05)。结论前列地尔联合倍他司汀治疗椎-基底动脉供血不足疗效显著。     

倍他司汀治疗眩晕症50例疗效观察

2004年7月-2005年4月我们用盐酸倍他司汀治疗各种眩晕症50例（包括耳源性眩晕、颈椎病所致眩晕、脑动脉硬化、椎-基底动脉供血不足、腔隙性脑梗死等，但不包括比较大的局灶性脑梗死、脑出血及直立性低血压所致眩晕），取得了比较满意的疗效，现报告如下。     

彩色多谱勒血流图对椎基底动脉供血不足患者的观察

目的:探讨彩色多谱勒血流图(CDFI)对椎基底动脉供血不足的诊断价值。方法:测定病例组和对照组的椎动脉内径、走形、收缩期峰值流速、阻力指数及搏动指数并进行比较。结果:椎基底动脉供血不足患者椎动脉走行异常者占34.8％,左侧椎动脉内径较对照组缩细,PSV与对照组同侧比较显著降低(P<0.05),RI与PI同侧比较显著增高(P<0.05)。结论:CDFI椎动脉的血流检测对椎基底动脉供血不足的诊断有客观、量化及实用价值。     

舒血宁注射液联合西比灵胶囊治疗血管性眩晕疗效观察

目的观察舒血宁注射液联合西比灵胶囊治疗血管性眩晕的临床疗效。方法将128例血管性眩晕患者随机分为治疗组和对照组,对照组给予盐酸倍他司汀氯化钠注射液250ml加入复方丹参注射液20 ml静脉滴注,1次/日,治疗7日;治疗组给予盐酸倍他司汀氯化钠注射液250ml加入舒血宁注射液15 ml静脉滴注,1次/日,西比灵胶囊5～10mg,每晚口服,治疗7日。治疗前后检测患者大脑中动脉(MCA)、大脑后动脉(PCA)、椎动脉(VA)、基底动脉(BA)血流速度。结果 治疗组有效率为96。9%(62/64),对照组有效率为85。9%(55/64),治疗组患者MCA、PCA、VA、BA血流情况较对照组显著改善,两组有效率差别具有统计学意义(P<0 05)。结论 舒血宁注射液联合西比灵胶囊可提高血管性眩晕的临床疗效,不良反应少,患者耐受性好。     

尼莫地平联合养血清脑颗粒治疗椎基底动脉供血不足性眩晕的临床观察

目的观察椎基底动脉供血不足性眩晕的中西医结合治疗疗效。方法59例椎基底动脉供血不足眩晕患者随机分为观察组32例,对照组27例;其中对照组给予尼莫地平注射液40 mg静滴,观察组在给予尼莫地平同时口服养血清脑颗粒3次/d,1包/次;上述两组给药14 d为1疗程。结果观察组治疗前后在椎动脉和基底动脉血流速度上比较均有统计学差异(P<0.05),总体疗效优于对照组(P<0.05)。结论尼莫地平联合养血清脑颗粒治疗椎基底动脉供血不足性眩晕疗效确定。     

椎基底动脉供血不足临床与TCD结果分析

目的：探讨椎基底动脉供血不足病人脑血流动力学改变与临床的相关性，提供临床医生在治疗过程的用药依据。方法：应用经颅彩色多谱勒[TCD]检测椎基底动脉供血不足的病人椎基度动脉系统的血流动力学。结果：临床诊断为椎基底动脉供血不足的病人，经TCD检查大多数有异常改变，可表现脑血流速度的变化[血流速度增快或减慢]，频谱形态及频谱性质的改变，以及转颈试验时峰值流速的变化。结论：TCD是一种无损伤性检查，简单、快速，可为医生诊断椎基底动脉脉供血不足提供重要的诊断依据，对医生选择用药有实际意义。     

半导体激光联合穴位注射治疗椎基底动脉缺血性眩晕

目的 观察半导体激光联合穴位注射治疗椎基底动脉缺血性眩晕的临床治疗效果.方法 椎基底动脉缺血性眩晕患者80例,随机分为2组,每组40例.治疗组以波长650 nm、功率50mw、光斑直径10mm、时间10 min半导体激光照射两侧风池穴,照射后于颈椎夹背穴注射血寨通注射液1.0～1.5 ml.对照组静脉点滴倍他司汀500ml加胞磷胆碱1.0 g.两组每口均治疗1次,6次为1疗程.2个疗程后观察治疗前后临床症状、主要症状积分、血液流变学、血栓素B2(thromboxane B2,TXB2)、血小板聚集率、左右椎动脉和椎基底动脉血流速度的变化.结果 两组总有效率分别为95.0%和77.5%,治疗组优于对照组(P＜0.05);治疗后两组主要症状均改善,治疗组优于对照组(P＜0.01);两组血液流变学、TXB2、血小板聚集率、椎基底动脉血流速度均有新改善,且治疗组优于对照组(P＜0.01,P＜0.05).结论 半导体激光联合穴位注射治疗椎基底动脉缺血性眩晕有较好的疗效.     

654-2、利多卡因联合治疗高原地区椎-基底动脉供血不足性眩晕的疗效观察

目的：探索高原地区椎—基底动脉供血不足(VBI)性眩晕的药物治疗。方法：治疗组654—2注射液20mg加入5．0％葡萄糖液500ml中静滴，1次／d，同时给予利多卡因点鼻，1滴～2滴／次，4次～5次／d，连用1周；对照组654—2注射液20mg加入5．0％葡萄糖液500ml中静滴，复方丹参液16ml加入10．0％葡萄糖液250ml中静滴，均1次／d，连用1周。同时治疗前后行彩色经颅多普勒(TCD)检查。结果：椎—基底动脉供血不足性眩晕经654—2及利多卡因联合治疗后大部分患者在短期内控制，显效率为70．0％，总有效率93．33％。结论：654—2及利多卡因联合治疗椎—基底动脉供血不足性眩晕疗效确切，且价格低廉，应用安全，见效快，值得临床推广。     

盐酸丁咯地尔注射液治疗椎-基底动脉供血不足疗效观察

我科对4年来住院的120例椎-基底动脉供血不足患者采用盐酸丁咯地尔（商品名：世多泰，海南惠普森医药生物技术有限公司）与常规药物治疗进行对比观察．分为治疗组与对照组．经观察盐酸丁咯地尔治疗椎-基底动脉供血不足取得较好疗效，现报告如下。     

高压氧对椎-基底动脉供血不足患者血流速度的影响

高压氧对椎┐基底动脉供血不足患者血流速度的影响李镇钦孟昕为探讨高压氧（ＨＢＯ）对椎－基底动脉（ＶＢＡ）血流速度的影响，对１４例经临床及经颅多普勒超声（ＴＣＤ）确诊为椎－基底动脉供血不足（ＶＢＩ）的患者予以ＨＢＯ治疗，并用ＴＣＤ测定ＶＢＡ治疗前后峰值流...     

硝苯地平对不明原因复发性流产患者子宫动脉血流动力学的影响

目的探讨硝苯地平对不明原因复发性流产患者子宫动脉血流动力学的影响。方法选取2019年6月~2020年5月在我院就诊的不明原因复发性流产102例患者为观察对象,随机将其分成观察组(53例)与对照组(49例)。对照组不采取任何诊治,观察组增加硝苯地平治疗。将两组患者诊治前、诊治7天后的子宫动脉血流动力学指标[PI(搏动指数)、RI(阻力指数)、S/D(收缩期峰值流速/舒张末期流速)]指标进行综合对比。结果治疗7天后,观察组患者的子宫动脉PI、RI、S/D水平均较治疗前下降,且对照组均高于实验组(P<0.05)。结论硝苯地平对不明原因复发性流产患者的子宫动脉血流动力学有改善作用且效果显著。     

椒苯酮胺对局灶性脑缺血再灌注损伤大鼠的神经保护作用

目的观察椒苯酮胺（piperphentonamine,PPTA）对大鼠脑缺血再灌注损伤后的保护作用,并探讨其作用机制。方法随机将SD大鼠分为假手术组、模型组、PPTA组（2.5,5,10 mg/kg）和阳性对照依达拉奉组（6 mg/kg）。采用大鼠大脑中动脉闭塞（MCAO）2 h再灌注模型,缺血1 h后静脉注射给药,复通灌流24 h后,采用Zea-Longa法进行神经功能缺陷评分,检测大鼠脑组织含水量,TTC染色法测定梗死体积及脑组织中SOD、MDA、GSH、NO、NOS生化指标。结果与模型组相比,PPTA组神经功能评分减低,梗死体积减少,脑组织中SOD、GSH活力增加,NOS活力降低,MDA和NO含量减少。其中以高剂量（10 mg/kg）组改变最为明显。结论 PPTA可能通过抑制脂质过氧反应和清除氧自由基等机制,发挥神经保护作用。     

盐酸司维拉姆与低钙透析液合用对血液透析患者相关血清指标的改善效果

 目的 探讨盐酸司维拉姆与低钙透析液联合应用对血液透析患者血清高密度脂蛋白、血磷、血清钙磷乘积变化及不良反应的影响。方法 选取医院2016-01至2018-01肾内科进行血液透析的慢性肾衰竭患者80例,分为对照组和试验组,每组40例,对两组患者采取不同的治疗方法:对照组采取常规血液透析治疗方法;试验组选用盐酸司维拉姆与低钙透析液进行联合治疗。治疗周期均为12周。治疗结束后,观察两组患者脂质代谢指标变化(TC、TG、LDL-C、HDL-C)、血钙、血磷、血清钙磷乘积变化及不良反应。结果 试验组患者在治疗前后,测得其血钙浓度并无显著变化(P>0.05),对照组患者治疗后血钙(2.75±0.35)mmol/L 浓度明显高于治疗前,差异有统计学意义(P<0.05);试验组患者治疗后TC(4.12±0.86) mmol/L、TG(1.21±0.64) mmol/L、LDL-C(2.14±0.38 mmol/L) 水平均显著低于对照组患者,而HDL-C水平(1.54±0.20)较对照组明显升高,差异有统计学意义(P<0.05);患者治疗后不良反应的总发生率为31.82％,明显高于对照组的18.18％(P<0.05)。结论 采取盐酸司维拉姆与低钙透析液联合治疗的方式,可有效改善血液透析患者血清高密度脂蛋白、血磷、血清钙磷乘积水平,疗效显著,且基本无严重不良反应发生。     

迭代重建技术在冠状动脉CTA扫描中的临床应用

目的探讨迭代重建技术在低剂量回顾性心电门控冠状动脉CTA扫描方案中应用的可行性。方法81例疑诊为冠心病患者随机纳入A组(100kVp)和B组(120kVp),行回顾性心电门控冠状动脉CTA成像,管电流峰值为500mA,A组数据进行ASIR重建,比例设定为30%。所得图像进行客观和主观评价,客观指标包括:血管强化程度(CT值),图像噪声(NI)和信噪比(SNR);主观评价指标采用Likert评分(4分)。所得各组指标进行统计学分析,P<0.05为具有统计学意义。结果与120kVp组相比,100kVp组冠状动脉血管强化程度及噪声明显增高,而其信噪比低于120kVp组。同时,100kVp组辐射剂量明显减低,两组图像主观评分无明显差异,均达到临床诊断要求。结论采用ASIR重建技术后的低辐射剂量冠状动脉CTA扫描方案,可显著提高冠状动脉血管强化程度,降低辐射剂量,而图像质量能够满足临床诊断需求。     

子宫动脉栓塞术联合米非司酮治疗子宫肌瘤的疗效

目的评价子宫动脉栓塞术联合米非司酮治疗子宫肌瘤的临床疗效。 方法回顾分析2006年4月至2012年4月93例子宫肌瘤患者的临床资料,其中48例行子宫动脉栓塞术联合米非司酮治疗（治疗组）,45例行单纯行子宫动脉栓塞术治疗（对照组）。比较两种方法的临床疗效。 结果治疗组治愈5例,好转28例,有效13例,无效2例,总显效率68.75%（33/48）;而对照组治愈3例,好转17例,有效21例,无效4例,总显效率44.44%（20/45）。治疗组显效率高于对照组（P<0.05）。 结论子宫动脉栓塞术联合米非司酮能有效提高子宫肌瘤治疗的显效率。     

Radiologically placed temporary hepatic artery catheter for treatment of liver cancer

Summary Hepatic artery infusion (HAI) chemotherapy is associated with higher response rates compared to systemic chemotherapy in those patients with unresectable liver malignancies. Operative hepatic artery catheter (HAC) insertion has significant morbidity and mortality, especially in patients with high-volume disease, some of whom may not respond to HAI chemotherapy. We report our experience in 45 patients with high-volume liver disease who were initially treated with HAI chemotherapy via a radiologically placed temporary HAC to try to select the responders who then went on to have an operative HAC. In these 45 patients who had 62 radiologically placed HAC, we found very few major complications, and certainly no complications such as cholecystitis, vascular or malperfusion problems.     

The use of coronary stent in hepatic artery stenosis after orthotopic liver transplantation

PURPOSE: This retrospective study was undertaken to evaluate the effectiveness of coronary stent placement in hepatic artery stenosis after orthotopic liver transplantation (OLT). MATERIALS AND METHODS: Of 430 consecutive adult orthotopic liver transplant recipients between November 2003 and September 2005, 17 had hepatic artery stenosis (HAS). Fourteen of them underwent coronary stent placement in the HAS. The technical results, complications, hepatic artery patency and clinical outcome were reviewed. RESULTS: Technical and immediate success was 100%. After a mean follow-up of 159.4 days (range, 9-375 days), all patients obtained patent hepatic arteries except 2 patients occurred hepatic artery restenoses at 26 and 45 days after stent placement, respectively. Kaplan-Meier curve of patency showed cumulated stent patency at 3, 6, and 12 months of 78%, 58% and 45%, respectively. During the follow-up, 8 patients survived, 5 died of septic multiple-organ failure, 1 received retransplantation because of refractory biliary infection. Hepatic artery dissection induced by a guiding catheter occurred in one patient and was successfully treated with a coronary stent. CONCLUSION: Hepatic artery stenosis after OLT can be successfully treated with coronary stent placement with low complication rate and an acceptable 1-year hepatic artery patency rate.     

Role of color-Doppler sonography in the follow-up of renal artery stenting

PURPOSE: The aim of this study was to evaluate the utility of color-Doppler ultrasound (CDUS) in detecting haemodynamically significant in-stent restenosis in patients who underwent endoluminal renal artery revascularisation by stent deployment. MATERIALS AND METHOD: Between January 2000 and December 2006, 42 patients (nine women and 33 men, age range 45-87 years) treated by endovascular renal artery stenting were studied with CDUS. Renal artery haemodynamics were evaluated to identify haemodynamically significant restenosis. Patients with CDUS signs of restenosis underwent angiography for a possible further revascularisation procedure. RESULT: Of 42 patients examined by CDUS, 13 (31%) showed signs of haemodynamically significant in-stent renal artery restenosis. Of these 13, three did not undergo endoluminal renal artery revascularisation because renal ischaemia deterioration and irreversible renal circulation impairment. In the remaining ten patients (23.8%), who had no signs of severe nephropathy, angiography confirmed the CDUS findings of in-stent restenosis in all cases. Restenoses were successfully treated by a repeat endovascular revascularisation procedure. CONCLUSION: Our results confirm the fundamental role of CDUS in the follow-up of patients after renal artery stenting. It enables early restenosis detection and evaluation of renovascular disease associated with renal artery stenosis. CDUS provides essential information for the subsequent clinical management of these patients.     

Emergent cervical internal carotid artery angioplasty before endovascular thrombectomy for acute ischemic stroke: a report of clinical and imaging outcome

A case of tandem occlusion consisting of right internal carotid artery (ICA) origin dissection and middle cerebral artery (MCA) thromoboembolism is reported. A 45 year-old male with right-sided neurological symptoms of emergent large vessel occlusion was treated with same-session angioplasty and mechanical thrombectomy of the respective lesions. The complete neurological recovery and radiological investigations are chronicled herein, and a review of the state of tandem occlusion management is discussed.